Camizestrant Links ESR1 Detection to Breast Cancer Care
FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while continuing CDK4/6 inhibitor therapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.